

Strategy, Programmes & Partnerships: Progress, Risks and Challenges

BOARD MEETING

Aurélia Nguyen

6-7 December 2023, Accra, Ghana



Balanced scorecard | Programmatic strategic goals

** Updated bi-annually or more (else updated annually)

Gavi 5.0 mission indicators

		Baseline (2020)	2022
Unique children immunised ¹	●	0	>133m (2021-22)
Future deaths averted	●	0	>2.4m (2021-22)
Reduction in zero-dose children	●	9m (2019)	10.2m
Future DALYs ² averted	●	0	>121m (2021-22)
Economic benefits unlocked	●	0	>\$35.8bn (2021-22)

SG1

Strategic goal 1

Introduce and scale up vaccines

		Baseline (2019)	H1 2023
Breadth of protection	●	48%	56% (2022)
New vaccine introductions**	●	n/a (2020)	7 (Sep 2023)
• HPV applications approved**	●	n/a	2 (Sep 23)
• Malaria applications approved**	●	n/a	16 (Sep 23)
Timely outbreak detection	●	25% ³	18% (2022)
Measles campaign reach	●	25%	70.2% (2022)

SG2

Strategic goal 2

Strengthen health systems

		Baseline (2019)	2022
DTP3 coverage	●	83%	81%
Geographic equity of DTP3	●	67%	62%
DTP dropout	●	6%	6%
MCV1 coverage	●	81%	79%

SG3

Strategic goal 3

Improve sustainability

		Baseline (2021)	H1 2023
Co-financing fulfilment	●	100% (2020)	30% ⁴
Preventing backsliding in Gavi-transitioned countries	●	8 countries ⁶	8 countries (2022)
Vaccine intro in transitioned & never-eligible countries	●	n/a (2022)	3 (Sep 2023)

SG4

Strategic goal 4

Ensure healthy markets

		Baseline	2022
Healthy market dynamics	●	n/a	10
Incentivise innovations	●	n/a	9
Scale-up innovations	●	n/a	2


● On track ● Delays/challenges ● Significant delays/challenges ● No target / TBD



SG1 As a testament to countries' continued focus on new introductions and scale-up, breadth of protection increased

Breadth of protection in Gavi-57 countries

%, 2019-2022



- Breadth of protection **increased by 5pp** in 2022 and now stands at 56%, remaining **on track for the Gavi 5.0 target**
- Breadth of protection in Gavi-supported countries is **higher than the rest of the world (56% vs. 53%)**


Source: WUENIC July 2023 release



Gavi 5.1 must-win: Update on HPV revitalisation

Latest forecast remains on track to meet 86 million target with upside potential

Cumulative girls reached with Gavi support, millions



- **16.3m girls vaccinated against HPV** with Gavi support by end 2022
- **Several major introductions ongoing** incl. Bangladesh, Indonesia and Nigeria
- **Programme is on track to reach the 86 m target;** high dependence on large population countries, e.g. India, Indonesia & Nigeria

Gavi 5.1 must-win: Malaria launch - 16 approved applications in 2023 and second vaccine recommended for Prequalification



“The arrival of the vaccines marks a historic step in our efforts to control malaria. We’re grateful for the support of our partners with whom we’re committed to working to ensure that the vaccines reach the children and protect them from this deadly disease.”


Hon Dr Malachie Manaouda, Minister of Public Health of Cameroon on the arrival of RTS,S Malaria vaccines on 21 Nov 2023

- **Strong demand and political will** for programme
 - **16 countries approved this year by Independent Review Committee (IRC)**
 - 9 non-MVIP countries targeting introductions by July 2024
 - 3 MVIP¹ countries to scale beyond pilot areas
 - 9 countries to receive doses by Jan 2024
- **A 2nd vaccine, R21, recommended by WHO**
 - **Supply expected to increase significantly** to enable more introductions and programme scale-up
 - **Country engagement underway** to optimise vaccine portfolios
 - Alliance working to **establish healthy market**
- Broader **programmatic and financial implications** of WHO-SAGE recommendations being reviewed
- **Joint Gavi-Global Fund-WHO discussions** underway related to country support for **optimal malaria control toolkit**



Routine immunisation showing signs of recovery

Variance in number of children vaccinated with DTP3 vs. 2019




Countries reached similar number of children in 2022 as 2019, but coverage not fully recovered due to population growth



Zero-dose decreased by 17% in 2022 – but 34% reduction needed to meet 2025 target and urgent catch-up needed post-pandemic

Number of zero-dose children across Gavi-57 countries
millions



Rapid acceleration in programming with ~50% of countries developing HSS/EAF grants in 2023; ~45% of HSS/EAF investments focused on ZD



SG2

Gavi 5.1 must-win: Board decision needed on the funding modalities of the Big Catch-Up (BCU)

Three objectives of the Big Catch-Up

1 **Catch-up** missed children



- Co-financing requirements in the context of countries' fiscal constraints could impede BCU implementation.
- PPC recommended that BCU be treated as a one-off, emergency effort and the Alliance be as permissive as possible while managing associated risks.
- Risk mitigation measures to protect core co-financing requirements would need to be put in place operationally, including assessment of in-country stock, phasing of supply, among others.
- Residual risks related to core co-financing, wastage and monitoring would likely persist.

2 **Restore** immunisation coverage

3 **Strengthen** health systems to reach zero-dose children

The Board is requested to approve flexibility to provide fully funded catch-up doses for children missed during the pandemic for an initial amount of US\$ 290 million subject to countries developing robust plans



Number of Gavi-transitioned countries with no backsliding remains on target

8

Countries maintained / increased DTP3 coverage

9

Countries experienced backsliding

- Number of Gavi-transitioned countries with no backsliding **remained stable at 2021 levels**, in line with **target** (no decline)
- Nine countries experienced backsliding, **demonstrating further potential to improve programmatic and financial sustainability**

Design of Gavi 6.0 strategy provides opportunity to reflect on programmatic and financial sustainability of transition model

No-cost extensions: Papua New Guinea (PNG) & Timor-Leste (TL)

PNG: no-cost extension of special strategy support until Dec 2027

- COVID-19 delayed PNG strategy – **completion by 2025 unlikely**
- Clear plan to **boost immunisation activities** over 2023-2027
- Extension would provide **funding stability and enable reforms**

TL: no-cost extension of post-transition support until Dec 2025

- **Exceptional post-transition grant in place** due to weak in-country capacity
- COVID-19 significantly **disrupted implementation**
- Extension will allow revisions to **address systemic weaknesses** under renewed government commitment and partner support

The Board is requested to approve the no-cost extensions for PNG and TL



Rotavirus supply disruptions have continued since downgrade to unacceptable market health in 2022

2022 vaccine market health

Acceptable

Unacceptable¹



Rotavirus ongoing supply disruptions in 2023:

- New production challenges affecting one supplier exposed countries to **risk of stockouts**
- Two countries agreed to **switch to an alternative presentation** to avoid this risk
- Alliance partners built on lessons learned from previous supply disruptions to **improve coordination and support to impacted countries**

1 - A total of three markets are now assessed as unacceptable requiring further intervention: rotavirus vaccine, oral cholera vaccine (OCV) and malaria vaccine. The human papillomavirus (HPV) market is assessed as unacceptable with conditions for improvement



Recommendations

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** flexibility for the Secretariat to provide fully funded catch-up doses for children missed during the pandemic for an initial amount of US\$ 290 million subject to countries developing robust plans and taking into account the risk mitigation measures as laid out in Annex D to Doc 04 as amended by discussions at the PPC;
- b) **Note** that the above approval reflects the urgent need for ambitious catch-up efforts for the period 2024-2025 and is contingent on available funding from the COVAX Advance Market Commitment (AMC) Pandemic Vaccine Pool (PVP) as confirmed by the Gavi Audit and Finance Committee;
- c) **Approve** that Papua New Guinea be exceptionally granted a no-cost extension of the US\$ 60 million 2019 Strategy funding envelope from December 2025 to December 2027, thereby extending the country's accelerated transition period to December 2027;
- d) **Request** an external review of the Papua New Guinea strategy be conducted by December 2026;
- e) **Approve** that Timor-Leste be exceptionally granted a no-cost extension of its post-transition support December 2023 to December 2025.

Thank you